The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis Academic Article uri icon

Overview

MeSH Major

  • Adalimumab
  • Antirheumatic Agents
  • Arthritis, Juvenile
  • Etanercept
  • Gene Expression Regulation
  • Tumor Necrosis Factor-alpha

abstract

  • JIA subjects with increased disease activity at baseline had higher serum pro-inflammatory cytokines. TNF-α inhibition resulted in suppression of IL-6 and IL-8 in parallel with clinical improvement in all anti-TNF treated subjects, but also was associated with elevated TNF-α and IL-17 in etanercept treated subjects. This article is protected by copyright. All rights reserved.

publication date

  • January 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4872381

Digital Object Identifier (DOI)

  • 10.1111/cei.12782

PubMed ID

  • 26934060

Additional Document Info